About ENDRA Life Sciences Inc. - Common Stock (NDRA)
Endra Life Sciences Inc is a pioneering medical technology company focused on enhancing non-invasive imaging techniques for better diagnosis and treatment guidance in healthcare. The company specializes in the development of its innovative Thermo Acoustic Imaging technology, which combines ultrasound and thermal imaging to provide real-time insights into tissue and organ function. By enabling clinicians to visualize metabolic conditions more effectively, Endra aims to improve patient outcomes in various areas, including liver health and cancer detection, while also streamlining the imaging process in medical practices. Read More
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”).
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster titled “Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity” for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled “Method and System for Monitoring Tissue Temperature.”
